Related Experiment Videos
Tc-99m MIBI to evaluate children with Ewing's sarcoma
Z Bar-Sever1, I J Cohen, L P Connolly
1Department of Nuclear Medicine, Rabin Medical Center, Petach-Tikva, Israel. barsev@isdn.net.il
Clinical Nuclear Medicine
|June 3, 2000
Summary
Technetium Tc-99m sestamibi (Tc-99m MIBI) imaging showed limited utility in managing pediatric Ewing
Area of Science:
- Nuclear Medicine
- Pediatric Oncology
- Radiopharmaceuticals
Background:
- Technetium Tc-99m sestamibi (Tc-99m MIBI) is increasingly used for tumor evaluation and assessing multidrug resistance.
- Its role in pediatric Ewing's sarcoma management requires further investigation.
Purpose of the Study:
- To evaluate the clinical utility of Tc-99m MIBI imaging in the management of pediatric Ewing's sarcoma.
- To correlate Tc-99m MIBI uptake with tumor characteristics and patient outcomes.
Main Methods:
- Retrospective review of 13 Tc-99m MIBI studies in 9 pediatric patients with Ewing's sarcoma.
- Evaluation of scintigraphy for tumor and metastasis uptake, correlated with clinical course and P-glycoprotein status.
Main Results:
- Tc-99m MIBI accumulated in 6 of 9 primary tumors but not in metastases.
- Uptake did not correlate with prognosis or P-glycoprotein status in most cases.
- Tc-99m MIBI was present in P-glycoprotein-positive tumors and one P-glycoprotein-negative tumor.
Conclusions:
- Tc-99m MIBI imaging demonstrated limited clinical utility in the management of pediatric Ewing's sarcoma.
- Further research may be needed to explore potential roles or refine imaging protocols.